This Content Component encountered an error
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
ESC TV – Guidelines

News and opinions on the latest ESC Clinical Practice Guidelines.

Watch now

Cancer treatments & cardiovascular toxicity 2016 (Position Paper)

This document reviews the different steps in cardiovascular monitoring and decision-makig before, during and after anticancer treatment with potential cardiovascular side-effects. This document aims to assist professionals involved in the treatment of patients with cancer and survivors by providing an expert consensus reading current standards of care for these individuals.

Cardio-Oncology
Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease


Guidelines version available to download

  • Published in: 2016
    Reference Eur Heart J (2016) 37 (36): 2768-2801- doi:10.1093/eurheartj/ehw211
  • Published in: 2016
    Reference
  • Published in: 2016
    Reference Online document
  • Published in: 2017
    Reference

Table of contents: Full Text (ESC Clinical Practice Guidelines)

Table of Contents

Abbreviations and acronyms

Preamble

Introduction

Cardiovascular complications of anticancer therapy: pathophysiology and management

  • Myocardial dysfunction and heart failure
  • Coronary artery disease
  • Valvular disease
  • Arrhythmias
  • Arterial hypertension
  • Thromboembolic disease
  • Peripheral vascular disease and stroke
  • Pulmonary hypertension
  • Other cardiovascular complications of anticancer treatment
  • Cardiovascular complications of anticancer treatment in special populations

Strategies for prevention and attenuation of cardiovascular complications of anticancer therapy

  • Treatment options to prevent or recover from cancer therapy-induced myocardial dysfunction
  • Prevention of thromboembolic events
  • Strategies for attenuation of complications related to use of specific agents

Long-term surveillance programmes for cancer survivors

  • Myocardial dysfunction
  • Vascular disease
  • Valvular disease

Future perspectives and research directions